Clinical trials: Placebo Response
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Venous Leg Ulcer
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
- Trial name
- NCT03077165
- Testing
- S42909 100 mg, S42909 200 mg, S42909 400 mg
- Where
- 80 sites in United States, Argentina and 9 more
- Volunteers
- 121 people
- Sponsor
- Ilkos Therapeutic Inc.
Crohn Disease
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index…
- Trial name
- NCT00552058
- Testing
- certolizumab pegol (CDP870, CZP)
- Where
- 116 sites in United States, Australia and 18 more
- Volunteers
- 439 people
- Sponsor
- UCB Pharma
Shock, Septic
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients…
- Trial name
- NCT03158948
- Testing
- Nangibotide 0.3 mg/kg, Nangibotide 1 mg/kg, Nangibotide 3 mg/kg
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Inotrem
Rheumatoid Arthritis
A Study in Moderate to Severe Rheumatoid Arthritis Participants
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had…
- Trial name
- RA-BUILD (NCT01721057)
- Testing
- Baricitinib, cDMARD
- Where
- 147 sites in United States, Argentina and 21 more
- Volunteers
- 684 people
- Sponsor
- Eli Lilly and Company
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Depression
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective…
- Trial name
- PREVAIL3 (NCT01284517)
- Testing
- Lurasidone
- Where
- 75 sites in United States, Canada and 8 more
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Gout
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an…
- Trial name
- NCT01399008
- Testing
- Arhalofenate, Allopurinol, Colchicine
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Cervical High Grade Squamous Intraepithelial Lesion
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors.
- Trial name
- NCT01928225
- Testing
- Human Papillomavirus vaccine
- Volunteers
- 180 people
- Sponsor
- University of Witwatersrand, South Africa
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to…
- Trial name
- SELECT-COMPARE (NCT02629159)
- Testing
- Adalimumab, Upadacitinib
- Where
- 370 sites in United States, Argentina and 42 more
- Volunteers
- 1,629 people
- Sponsor
- AbbVie
Primary Biliary Cholangitis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
- Trial name
- NCT03394924
- Testing
- EDP-305 1 mg, EDP-305 2.5 mg
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 68 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Depressive Disorder, Major
AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment
We hypothesize that AndroGel may offer some relief to subjects with low or borderline testosterone levels who suffer from depression and have failed to respond to a trial of a standard antidepressant.
- Trial name
- NCT00304746
- Testing
- Testosterone gel
- Where
- 2 sites in United States, Israel
- Volunteers
- 100 people
- Sponsor
- Mclean Hospital
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Healthy Volunteers
SPM Regulation by Fish Oil Supplements in Healthy Volunteers
A randomised, double-blind, placebo-controlled study to determine whether fish oil supplementation regulates peripheral levels of specialized pro-resolving mediators and white blood cell responses in healthy volunteers
- Trial name
- NCT03347006
- Testing
- SPM Active
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Septic Shock
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and…
- Trial name
- SEPSIS-ACT (NCT02508649)
- Testing
- selepressin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 868 people
- Sponsor
- Ferring Pharmaceuticals
Migraine
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine.
- Trial name
- NCT00442936
- Testing
- Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX…
- Trial name
- 986 (NCT01999192)
- Testing
- Tregalizumab
- Where
- 84 sites in United States, Bulgaria and 12 more
- Volunteers
- 321 people
- Sponsor
- Biotest
Healthy
Variability in Response to Non-steroidal Anti-inflammatory Drugs
This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults.
- Trial name
- NCT02502006
- Testing
- Celecoxib, Naproxen
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Irritable Bowel Syndrome, Placebo Effect
Effects of Open-label vs Double-blind Treatment in IBS
The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
- Conditions
- Irritable Bowel Syndrome, Placebo Effect, Placebos, Peppermint Oil
- Trial name
- NCT02802241
- Testing
- peppermint oil
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Beth Israel Deaconess Medical Center